Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: Illustrated are a switched-capacitor DC-DC convertor and a control method thereof. The switched-capacitor DC-DC convertor includes a switched-capacitor circuit, a latched comparator and a clock generating module. The switched-capacitor circuit converts an input voltage into an output voltage through a phase switching operation. The latched comparator receives a clock signal, and compares the output voltage and a reference voltage according to the clock signal, to generate the control signal, which triggers a phase switching operation of the switched-capacitor circuit. The clock generating module generates the clock signal, and adjusts a frequency of the clock signal according to variation of the control signal.

Abstract: System and methods are disclosed for identifying and isolating antibodies with specific affinity with an antigen of interest. Multiple DNA libraries encoding antibodies or their fragments are designed such that the encoded antibodies from different libraries are tagged differently. These libraries may be transformed into yeast cells. The variants of the antibodies are displayed on the surface of the yeast cells and flow cytometry may be used to sort the cells based on antigen affinity and the different tags on the antibodies. By allowing multiple libraries to be screened simultaneously, the disclosed methods help improve the efficiency of affinity.

Abstract: The present disclosure illustrates a dual-mode regulator circuit comprising: a first output terminal; a second output terminal; a switching regulator circuit coupled to the first output terminal and comprising a first transistor coupled between the first output terminal and ground; a linear regulator circuit coupled to the second output terminal and comprising a second transistor coupled between the second output terminal and a power source; a detection circuit configured to turn on the first transistor in order to connect the first output terminal to ground, turn on the second transistor in order to connect the second output terminal to the power source, and then generate a detection signal indicating whether an inductor is connected between the first and second output terminals; and a logic circuit configured to activate the switching regulator circuit or the linear regulator circuit according to the detection signal.

Abstract: A DC-DC power converter circuit includes a switched-capacitor circuit, an error amplifier, a latched comparator and a switching controller. The error amplifier adjusts an error amplification signal of the error amplifier in response to an output voltage of the switched-capacitor circuit and a reference voltage. The error amplification signal is then fed to the latched comparator as a comparison reference, resulting in the DC-DC power converter circuit being able to more precisely maintain the output voltage within a predetermined range.

Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Abstract: The present disclosure illustrates a dual-mode regulator circuit comprising: a first output terminal; a second output terminal; a switching regulator circuit coupled to the first output terminal and comprising a first transistor coupled between the first output terminal and ground; a linear regulator circuit coupled to the second output terminal and comprising a second transistor coupled between the second output terminal and a power source; a detection circuit configured to turn on the first transistor in order to connect the first output terminal to ground, turn on the second transistor in order to connect the second output terminal to the power source, and then generate a detection signal indicating whether an inductor is connected between the first and second output terminals; and a logic circuit configured to activate the switching regulator circuit or the linear regulator circuit according to the detection signal.

Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.

Abstract: A power optimization device and method thereof for energy harvesting apparatus are disclosed. The power optimization device includes a charge pump, a voltage comparator, an output switch, a counter and a frequency control module. By detecting the voltage outputted from the power optimization device under various operating frequencies to obtain a calculation result and increase or decrease an operating frequency of the charge pump according to the calculation result, so as to dynamically adjust the operating frequency to optimize the power outputted from the power optimization device according to the voltage outputted from the energy harvesting apparatus to an electricity storage unit and energy loss caused by the change of the operating frequency.

Abstract: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.

Abstract: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).

Abstract: The present invention relates to improved methods for antibody engineering, e.g., humanization. In particular, the disclosure provides a high-throughput antibody humanization process that can be automated by computer-implementation.

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.